Lampiran 2
LEMBAR PENJELASAN KEPADA CALON SUBJEK PENELITIAN
Selamat pagi/siang Bapak/Ibu/Saudara/I, pada hari ini saya, dr.Eva
Roswati, peserta Pendidikan Pasca Sarjana Ilmu Penyakit Dalam / Magister
Klinik FK USU Medan akan melakukan penelitian yang berjudul ” Pengaruh
pemberian rejimen antiretroviral (ARV) yang mengandung Zidovudine atau
Tenofovir terhadap
kadar lipid pada orang dengan HIV/AIDS (ODHA)”.
Penelitian ini bertujuan melihat pengaruh pemberian obat antiretroviral yang
mengandung Zidovudine atau Tenofovir selama 6 bulan terhadap kadar lipid
serum. Sebagai informasi, yang dikatakan sebagai penderita HIV-AIDS adalah
subyek yang terinfeksi virus HIV yang memerlukan terapi obat anti virus untuk
mengobati penyakitnya. Diperlukan kepatuhan untuk meminum obat anti virus
tersebut agar keberhasilan terapi dapat tercapai. Namun demikian, pemberian obat
anti virus juga mempengaruhi kadar lipid. Untuk itu peneliti ingin mengetahui
apakah ada hubungan antara obat tersebut dengan kadar lipid .
Bapak/Ibu/Saudara/Saudari yang bersedia mengikuti penelitian ini
nantinya akan diminta mengisi surat persetujuan ikut dalam penelitian, mengikuti
wawancara untuk mencari adanya hal-hal yang dapat mengganggu penelitian.
Untuk penelitian ini akan dilakukan pengambilan darah pada daerah lipatan siku
Bapak/Ibu/Saudara/i sebanyak ±15 cc (1 sendok makan) oleh ahlinya untuk
pemeriksaan darah rutin, fungsi hati, fungsi ginjal, kadar glukosa darah, kadar
lipid setelah Bapak/Ibu berpuasa 12-16jam semalam sebelum pengambilan darah.
Di akhir minggu ke 24 nantinya akan dilakukan pemeriksaan ulangan untuk
menilai efek apakah terdapat pengaruh dalam hal ini: kadar lipid dari pemberian
obat antiretroviral yang telah Bapak/Ibu/Saudara/Saudari minum. Segala biaya
pemeriksaan laboratorium menjadi tanggung jawab peneliti. Bila masih terdapat
pertanyaan
atau
keluhan
sewaktu
penelitian
ini
berjalan,
maka
Bapak/Ibu/Saudara/Saudari dapat menghubungi saya pada:
Nama
: dr.Eva Roswati
Alamat
: Jl. Gajah Mada No. 14 Medan
Telepon
: 08116074047
Atas Perhatian Bapak/Ibu, Saudara/i saya ucapkan terima kasih.
Peneliti,
Lampiran 3
LEMBAR PERSETUJUAN SETELAH PENJELASAN
(INFORMED CONSENT)
Saya yang bertandatangan di bawah ini:
Nama
: ...
Alamat
: ...
Umur
: ...
Jenis Kelamin : Laki-laki/ Perempuan
No Telp
: ...
Setelah mendapat penjelasan dari peneliti tentang kebaikan dan keburukan
prosedur penelitian ini, saya menyatakan bersedia ikut serta dalam penelitian
tentang
“
Pengaruh pemberian rejimen antiretroviral (ARV) yang
mengandung Zidovudine atau Tenofovir terhadap kadar lipid pada orang
dengan HIV/AIDS (ODHA)
”.
Apabila sewaktu-waktu saya mengudurkan diri
dari penelitian ini, kepada saya tidak dituntut apapun.
Demikian surat persetujuan bersedia ikut dalam penelitian ini saya buat untuk
dapat dipergunakan seperlunya.
Medan,
………..
Saksi Yang memberi pernyataan
Lampiran 4
KERTAS KERJA PROFIL PESERTA PENELITIAN
I. IDENTITAS PRIBADI.
Nama : ...
Umur
: ...
Jenis Kelamin
: Laki-laki/Perempuan.
Pendidikan Terakhir
: ...
Parameter Antropometri
Hasil
Berat Badan (kg)
Tinggi Badan (m
2)
Hitung jenis lekosit
Ureum
Kreatinin
SGOT
SGPT
Lampiran 5
DAFTAR RIWAYAT HIDUP
I.
Identitas Pribadi
Nama : dr. Eva Roswati
Tempat/Tgl Lahir : Jakarta/ 24 November 1977
Suku/Bangsa : Batak/ Indonesia
Agama : Kristen Protestan
Status : Menikah
Alamat : Jl. Gajah Mada Gg. Sersan No. 14 Medan
Telpon Selluler : 08116074047
II.
Keluarga
Nama suami : Ir. Sarma Aries H. Lumban Gaol
Anak : 1. Josh Richard Lumban Gaol
2.
Daireann Ersah Lumban Gaol
III.
Pendidikan
SDN 09 Pagi Ragunan, Jakarta
Tamat Tahun 1989
SMPN 175 Jagakarsa, Jakarta
Tamat Tahun 1992
SMAN 28 Pasar Minggu, Jakarta
Tamat Tahun 1995
Fakultas Kedokteran Universitas Sumatera Utara
Tamat Tahun 2001
PPDS Ilmu Penyakit Dalam FK USU
2010 - sekarang
IV.
Riwayat Pekerjaan
Dokter ICU RSPAD Gatot Soebroto, Jakarta
Dokter PTT RSU Dr. Hadrianus Sinaga Pangururan, Samosir
Dokter UGD RSPAD Gatot Soebroto, Jakarta
V.
Perkumpulan Profesi
Anggota IDI Cabang Medan
Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI)
VI.
Tulisan Ilmiah
1.
Diagnosis dan Tatalaksana Koagulasi Intravaskular Diseminata pada
Sepsis
2.
Insufisiensi adrenal pada pasien dengan penyakit kritis
3.
Dispepsia Tukak : Diagnosis dan Manajemen
4.
Makna Klinis Kadar Troponin T pada penyakit jantung
5.
Pemakaian Obat-obat sistemik pada penyakit ginjal kronik
6.
Acute Respiratory Distress Syndrome
7.
Manifestasi Klinis dari Alergi Makanan
8.
Penggunaan sistem skor sebagai panduan thromboprofilaksis pada
populasi ibu hamil dengan resiko tinggi
9.
Bagaimana manifestasi jiwa yang sehat
VII.
Publikasi Ilmiah
1.
Sindroma
Cushing
Iatrogenik
dan
Dermatitis
Eksfoliativa
Generalisata: Laporan Kasus. 4 th Endocrinology & Diabetes Forum
Of Sumatera Region. Banda Aceh, 2012.
2.
Pengalaman Menangani Kasus Serial Malaria Berat di RS H.Adam
Malik Tahun 2011
–
Mei 2012 : Laporan Kasus. PETRI, Banda Aceh,
2012
VIII.
Partisipasi Dalam Kegiatan Ilmiah
1.
Peserta Simposium
“The New Option of Insulin Resistance Treatment
in Type 2 Diabetes
”, Hermes Palace Hotel Medan, 20 November 2011
3.
Peserta Simposium “Rationale Strategy in the Management of
Pancreatic B Dysfunction and Role of Oral Incretin Based Therapy in
Type 2 Diabetes Mellitus”, Hotel J.W. Marriott Medan, 29 Januari
2012.
4.
Peserta Simposium
The New Direction in The Treatment of Type 2
Diabetes Melitus “A New Novel DPP
-4 Inhibitor For T2DM
Treat
ment”
, Hotel J.W. Marriott Medan, 1 April 2012
5.
Peserta Roadshow Hipertensi PB PAPDI “
The Next Big Target in
Hypertension: Controlling All Key BP Parameters”
, Hotel J.W.
Marriott Medan, 28 April 2012
6.
Peserta Seminar dan Lokakarya Sehari:
Comperhensive Management
of Nausea-Vomiting and Acid Related Diseases
, 5 Mei 2012.
7.
Peserta Simposium “Diagnostik dan Manajemen Terkini di Bidang
Ilmu Penyakit Dalam, Fokus pada Infeksi”. PIT Penyakit Dalam XIII
& Infection Update V. Hotel Danau Toba Internasional. Medan, 9-10
Juni 2012.
8.
Peserta Simposium Kongres Nasional XV Perhimpunan Dokter
Spesialis Penyakit Dalam Indonesia (KOPAPDI XV), Hotel J.W.
Marriott dan Hotel Grand Aston Medan, 12-15 Desember 2012
9.
Peserta Workshop USG PAD, FEDS V, Hotel Grand Aston Medan,
Februari 2013
10.
Panitia Workshop & Simposium
“Meningkatkan Kemampuan Dalam
Menghadapi Penyakit Infeksi Masa Kini”
Infection Update VI. PETRI
SUMUT. Hotel Danau Toba Internasional. Medan 6-7 September
2013.
11.
Peserta Workshop
“USG”
. Pertemuan Ilmiah Tahunan Ilmu Penyakit
Dalam XIV & Gastroentero-Hepatologi Update XI. Hotel Tiara
Convention Center. Medan 12-14 September 2013.
Lampiran 6
HASIL STATISTIK
Karakteristik Dasar Subjek Penelitian
Crosstab Jenis kelamin
rejimen Total
Naive Zidovudine Tenofovir
jk Laki-laki Count 11 12 14 37
Expected Count 12,3 12,3 12,3 37,0
% within jk 29,7% 32,4% 37,8% 100,0%
% within rejimen 52,4% 57,1% 66,7% 58,7%
Perempuan Count 10 9 7 26
Expected Count 8,7 8,7 8,7 26,0
% within jk 38,5% 34,6% 26,9% 100,0%
% within rejimen 47,6% 42,9% 33,3% 41,3%
Total Count 21 21 21 63
Expected Count 21,0 21,0 21,0 63,0
% within jk 33,3% 33,3% 33,3% 100,0%
% within rejimen 100,0% 100,0% 100,0% 100,0%
Chi-Square Tests
Value df
Asymp. Sig.
(2-sided)
Pearson Chi-Square ,917a 2 ,632
Likelihood Ratio ,926 2 ,629
Linear-by-Linear Association ,870 1 ,351
N of Valid Cases 63
Crosstab Pendidikan
rejimen
Total Naive Zidovudine Tenofovir
pendidikan SD Count 1 5 1 7
Linear-by-Linear Association 1,779 1 ,182
N of Valid Cases 63
a. 9 cells (60,0%) have expected count less than 5. The minimum
Crosstab Pekerjaan
rejimen
Total Naive Zidovudine Tenofovir
% within pekerjaan 33,3% 33,3% 33,3% 100,0%
Pearson Chi-Square 11,789a 14 ,623
Likelihood Ratio 12,818 14 ,541
Linear-by-Linear Association ,050 1 ,824
N of Valid Cases 63
a. 21 cells (87,5%) have expected count less than 5. The minimum
expected count is ,33.
Crosstab Faktor Risiko
rejimen
Total Naive Zidovudine Tenofovir
Expected Count ,7 ,7 ,7 2,0
Pearson Chi-Square 12,592a 10 ,247
Likelihood Ratio 15,959 10 ,101
Linear-by-Linear Association ,726 1 ,394
N of Valid Cases 63
a. 15 cells (83,3%) have expected count less than 5. The minimum
expected count is ,33.
Descriptives Usia, IMT dan CD4
rejimen Statistic Std. Error
usia Naive Mean 35,2381 1,85023
95% Confidence Interval for
Mean
Lower Bound 31,3786
Upper Bound 39,0976
5% Trimmed Mean 34,9259
Median 33,0000
Variance 71,890
Std. Deviation 8,47883
Minimum 22,00
Maximum 54,00
Range 32,00
Interquartile Range 11,00
Skewness ,826 ,501
Kurtosis ,105 ,972
Zidovudine Mean 36,3810 2,14640
95% Confidence Interval for
Mean
Lower Bound 31,9036
Upper Bound 40,8583
5% Trimmed Mean 35,9233
Median 35,0000
Std. Deviation 9,83604
Minimum 21,00
Maximum 60,00
Range 39,00
Interquartile Range 13,50
Skewness ,893 ,501
Kurtosis ,410 ,972
Tenofovir Mean 33,8571 2,23744
95% Confidence Interval for
Mean
Lower Bound 29,1899
Upper Bound 38,5244
5% Trimmed Mean 33,1164
Median 30,0000
Variance 105,129
Std. Deviation 10,25322
Minimum 21,00
Maximum 60,00
Range 39,00
Interquartile Range 8,00
Skewness 1,534 ,501
Kurtosis 1,959 ,972
IMT Naive Mean 20,7190 ,65526
95% Confidence Interval for
Mean
Lower Bound 19,3522
Upper Bound 22,0859
5% Trimmed Mean 20,6254
Median 21,2000
Variance 9,017
Std. Deviation 3,00277
Minimum 15,90
Maximum 27,30
Range 11,40
Interquartile Range 3,90
Skewness ,165 ,501
Kurtosis -,037 ,972
Zidovudine Mean 23,2000 ,75763
95% Confidence Interval for
Mean
Lower Bound 21,6196
Upper Bound 24,7804
5% Trimmed Mean 23,0767
Variance 12,054
Std. Deviation 3,47189
Minimum 17,60
Maximum 31,00
Range 13,40
Interquartile Range 3,90
Skewness ,775 ,501
Kurtosis ,830 ,972
Tenofovir Mean 22,0333 ,73515
95% Confidence Interval for
Mean
Lower Bound 20,4998
Upper Bound 23,5668
5% Trimmed Mean 21,8471
Median 21,8000
Variance 11,349
Std. Deviation 3,36888
Minimum 17,10
Maximum 30,40
Range 13,30
Interquartile Range 3,65
Skewness ,962 ,501
Kurtosis ,897 ,972
CD4 Naive Mean 152,8571 30,47077
95% Confidence Interval for
Mean
Lower Bound 89,2962
Upper Bound 216,4181
5% Trimmed Mean 143,7090
Median 136,0000
Variance 19497,829
Std. Deviation 139,63463
Minimum 7,00
Maximum 467,00
Range 460,00
Interquartile Range 239,50
Skewness ,772 ,501
Kurtosis -,427 ,972
Zidovudine Mean 333,7143 31,44369
95% Confidence Interval for
Mean
Lower Bound 268,1239
Upper Bound 399,3047
Median 316,0000
Variance 20762,814
Std. Deviation 144,09308
Minimum 92,00
Maximum 633,00
Range 541,00
Interquartile Range 222,00
Skewness ,243 ,501
Kurtosis -,360 ,972
Tenofovir Mean 306,7143 44,09493
95% Confidence Interval for
Mean
Lower Bound 214,7339
Upper Bound 398,6947
5% Trimmed Mean 291,8122
Median 260,0000
Variance 40831,614
Std. Deviation 202,06834
Minimum 84,00
Maximum 799,00
Range 715,00
Interquartile Range 272,50
Skewness 1,225 ,501
Kurtosis 1,100 ,972
Tests of Normality Usia, IMT, CD4
rejimen
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
*. This is a lower bound of the true significance.
Profil Lipid berdasarkan rejimen pengobatan
Descriptives kadar profil lipid
rejimen Statistic Std. Error
kolest Naive Mean 145,2857 6,39350
95% Confidence Interval for
Mean
Lower Bound 131,9491
Upper Bound 158,6223
5% Trimmed Mean 142,7354
Median 138,0000
Variance 858,414
Std. Deviation 29,29871
Minimum 99,00
Maximum 239,00
Range 140,00
Interquartile Range 29,50
Skewness 1,685 ,501
Kurtosis 4,431 ,972
Zidovudine Mean 189,7143 5,38169
95% Confidence Interval for
Mean
Lower Bound 178,4883
Upper Bound 200,9403
5% Trimmed Mean 189,9048
Median 195,0000
Variance 608,214
Std. Deviation 24,66200
Minimum 144,00
Maximum 232,00
Range 88,00
Interquartile Range 39,00
Skewness -,031 ,501
Kurtosis -,856 ,972
Tenofovir Mean 200,8095 11,31342
95% Confidence Interval for
Mean
Lower Bound 177,2101
Upper Bound 224,4089
5% Trimmed Mean 201,7116
Median 217,0000
Variance 2687,862
Minimum 105,00
Maximum 281,00
Range 176,00
Interquartile Range 82,50
Skewness -,394 ,501
Kurtosis -,832 ,972
trigliserid Naive Mean 123,4286 8,44691
95% Confidence Interval for
Mean
Lower Bound 105,8086
Upper Bound 141,0485
5% Trimmed Mean 123,2937
Median 129,0000
Variance 1498,357
Std. Deviation 38,70862
Minimum 53,00
Maximum 197,00
Range 144,00
Interquartile Range 56,00
Skewness -,151 ,501
Kurtosis -,455 ,972
Zidovudine Mean 123,0000 11,97299
95% Confidence Interval for
Mean
Lower Bound 98,0248
Upper Bound 147,9752
5% Trimmed Mean 121,0873
Median 113,0000
Variance 3010,400
Std. Deviation 54,86711
Minimum 46,00
Maximum 235,00
Range 189,00
Interquartile Range 84,50
Skewness ,620 ,501
Kurtosis -,410 ,972
Tenofovir Mean 153,3333 20,41957
95% Confidence Interval for
Mean
Lower Bound 110,7389
Upper Bound 195,9278
5% Trimmed Mean 148,9815
Median 129,0000
Variance 8756,133
Minimum 30,00
Maximum 355,00
Range 325,00
Interquartile Range 117,50
Skewness 1,076 ,501
Kurtosis ,487 ,972
HDL Naive Mean 30,9524 2,08335
95% Confidence Interval for
Mean
Lower Bound 26,6066
Upper Bound 35,2982
5% Trimmed Mean 30,8042
Median 34,0000
Variance 91,148
Std. Deviation 9,54713
Minimum 12,00
Maximum 53,00
Range 41,00
Interquartile Range 13,00
Skewness -,142 ,501
Kurtosis ,556 ,972
Zidovudine Mean 49,6667 2,75451
95% Confidence Interval for
Mean
Lower Bound 43,9209
Upper Bound 55,4125
5% Trimmed Mean 49,6190
Median 47,0000
Variance 159,333
Std. Deviation 12,62273
Minimum 29,00
Maximum 71,00
Range 42,00
Interquartile Range 23,00
Skewness ,193 ,501
Kurtosis -,979 ,972
Tenofovir Mean 44,9524 2,97408
95% Confidence Interval for
Mean
Lower Bound 38,7486
Upper Bound 51,1562
5% Trimmed Mean 44,5185
Median 42,0000
Variance 185,748
Minimum 25,00
Maximum 73,00
Range 48,00
Interquartile Range 17,50
Skewness ,504 ,501
Kurtosis -,398 ,972
LDL Naive Mean 91,5714 5,68103
95% Confidence Interval for
Mean
Lower Bound 79,7210
Upper Bound 103,4219
5% Trimmed Mean 89,8413
Median 88,0000
Variance 677,757
Std. Deviation 26,03377
Minimum 55,00
Maximum 160,00
Range 105,00
Interquartile Range 23,00
Skewness 1,121 ,501
Kurtosis 1,429 ,972
Zidovudine Mean 123,0000 6,36134
95% Confidence Interval for
Mean
Lower Bound 109,7305
Upper Bound 136,2695
5% Trimmed Mean 121,1190
Median 122,0000
Variance 849,800
Std. Deviation 29,15133
Minimum 71,00
Maximum 211,00
Range 140,00
Interquartile Range 36,50
Skewness 1,094 ,501
Kurtosis 3,165 ,972
Tenofovir Mean 124,5238 8,15844
95% Confidence Interval for
Mean
Lower Bound 107,5056
Upper Bound 141,5420
5% Trimmed Mean 125,5794
Variance 1397,762
Std. Deviation 37,38665
Minimum 46,00
Maximum 183,00
Range 137,00
Interquartile Range 58,50
Skewness -,371 ,501
Kurtosis -,571 ,972
Tests of Normality
rejimen
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
kolest Naive ,150 21 ,200* ,869 21 ,009
Zidovudine ,109 21 ,200* ,970 21 ,733
Tenofovir ,146 21 ,200* ,955 21 ,417
trigliserid Naive ,098 21 ,200* ,981 21 ,935
Zidovudine ,135 21 ,200* ,941 21 ,229
Tenofovir ,203 21 ,024 ,880 21 ,015
HDL Naive ,163 21 ,150 ,948 21 ,313
Zidovudine ,115 21 ,200* ,953 21 ,387
Tenofovir ,157 21 ,190 ,946 21 ,284
LDL Naive ,168 21 ,124 ,908 21 ,050
Zidovudine ,140 21 ,200* ,918 21 ,078
UJI ANOVA
Sum of Squares df Mean Square F Sig.
IMT Between Groups 64,705 2 32,353 2,994 ,058
Within Groups 648,399 60 10,807
Total 713,104 62
Within Groups 335648571428,5
71 60 5594142857,143
Total 361280857142,8
57 62
HDL Between Groups 3979,143 2 1989,571 13,683 ,000
Within Groups 8724,571 60 145,410
Total 12703,714 62
LDL Between Groups 14531,556 2 7265,778 7,451 ,001
Within Groups 58506,381 60 975,106
Total 73037,937 62
Post Hoc Tests
Multiple Comparisons
Bonferroni
Dependent
Variable (I) rejimen (J) rejimen
Mean Difference
(I-J) Std. Error Sig.
95% Confidence Interval
Lower Bound Upper Bound
IMT Naive Zidovudine -2,48095 1,01450 ,052 -4,9796 ,0177
Tenofovir -48000,00000 23081,93038 ,126 -104849,7139 8849,7139
Zidovudine Naive 34142,85714 23081,93038 ,433 -22706,8568 90992,5710
Tenofovir -13857,14286 23081,93038 1,000 -70706,8568 42992,5710
Tenofovir Naive 48000,00000 23081,93038 ,126 -8849,7139 104849,7139
Zidovudine 13857,14286 23081,93038 1,000 -42992,5710 70706,8568
HDL Naive Zidovudine -18,71429* 3,72136 ,000 -27,8798 -9,5487
Tenofovir -14,00000* 3,72136 ,001 -23,1655 -4,8345
Zidovudine Naive 18,71429* 3,72136 ,000 9,5487 27,8798
Proporsi Kadar Lipid berdasarkan kriteria dislipidemia
Kolesterol totalFrequency Percent Valid Percent
Cumulative
Frequency Percent Valid Percent
Cumulative
Frequency Percent Valid Percent
Cumulative
Frequency Percent Valid Percent
Cumulative
Zidovudine -4,71429 3,72136 ,630 -13,8798 4,4513
LDL Naive Zidovudine -31,42857* 9,63677 ,005 -55,1635 -7,6937
Tenofovir -32,95238* 9,63677 ,003 -56,6873 -9,2175
Zidovudine Naive 31,42857* 9,63677 ,005 7,6937 55,1635
Tenofovir -1,52381 9,63677 1,000 -25,2587 22,2111
Tenofovir Naive 32,95238* 9,63677 ,003 9,2175 56,6873
Zidovudine 1,52381 9,63677 1,000 -22,2111 25,2587
Dislipidemia
Frequency Percent Valid Percent
Cumulative
Percent
Valid ya 50 79,4 79,4 79,4
tidak 13 20,6 20,6 100,0
Total 63 100,0 100,0
jk * Dislipidemia Crosstabulation
Dislipidemia
% within Dislipidemia 100,0% 100,0% 100,0%
Chi-Square Tests
Continuity Correctionb ,000 1 1,000
Likelihood Ratio ,054 1 ,817
Fisher's Exact Test 1,000 ,538
Linear-by-Linear Association ,052 1 ,819
N of Valid Cases 63
a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 5,37.
Risk Estimate
Value
95% Confidence Interval
Lower Upper
Odds Ratio for jk (Laki-laki /
Perempuan) ,863 ,247 3,014
For cohort Dislipidemia = ya ,970 ,754 1,249
For cohort Dislipidemia =
tidak 1,124 ,414 3,051
N of Valid Cases 63
Descriptives
Dislipidemia Statistic Std. Error
usia ya Mean 36,2400 1,38639
95% Confidence Interval for
Mean
Lower Bound 33,4539
Upper Bound 39,0261
5% Trimmed Mean 35,6556
Median 33,0000
Variance 96,104
Std. Deviation 9,80329
Minimum 22,00
Maximum 60,00
Range 38,00
Interquartile Range 13,25
Skewness 1,017 ,337
Kurtosis ,178 ,662
tidak Mean 31,0000 1,87767
95% Confidence Interval for
Mean
Lower Bound 26,9089
Upper Bound 35,0911
5% Trimmed Mean 30,8889
Median 29,0000
Variance 45,833
Std. Deviation 6,77003
Minimum 21,00
Maximum 43,00
Range 22,00
Skewness ,324 ,616
Kurtosis -,400 1,191
IMT ya Mean 21,8640 ,50907
95% Confidence Interval for
Mean
Lower Bound 20,8410
Upper Bound 22,8870
5% Trimmed Mean 21,6867
Median 21,6000
Variance 12,957
Std. Deviation 3,59965
Minimum 15,90
Maximum 31,00
Range 15,10
Interquartile Range 4,02
Skewness ,765 ,337
Kurtosis ,638 ,662
tidak Mean 22,4462 ,69195
95% Confidence Interval for
Mean
Lower Bound 20,9385
Upper Bound 23,9538
5% Trimmed Mean 22,4457
Median 22,0000
Variance 6,224
Std. Deviation 2,49487
Minimum 17,60
Maximum 27,30
Range 9,70
Interquartile Range 3,30
Skewness ,015 ,616
Kurtosis ,458 1,191
CD4 ya Mean 252,2400 27,10800
95% Confidence Interval for
Mean
Lower Bound 197,7644
Upper Bound 306,7156
5% Trimmed Mean 237,9556
Median 207,5000
Variance 36742,186
Std. Deviation 191,68251
Minimum 7,00
Maximum 799,00
Interquartile Range 269,00
Skewness ,958 ,337
Kurtosis ,733 ,662
tidak Mean 311,3077 34,46038
95% Confidence Interval for
Mean
Lower Bound 236,2250
Upper Bound 386,3904
5% Trimmed Mean 312,8974
Median 316,0000
Variance 15437,731
Std. Deviation 124,24867
Minimum 111,00
Maximum 483,00
Range 372,00
Interquartile Range 182,00
Skewness -,317 ,616
Kurtosis -,901 1,191
Tests of Normality
Dislipidemia
Kolmogorov-Smirnova Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
usia ya ,170 50 ,001 ,893 50 ,000
tidak ,175 13 ,200* ,933 13 ,368
IMT ya ,125 50 ,049 ,944 50 ,020
tidak ,109 13 ,200* ,988 13 ,999
CD4 ya ,111 50 ,167 ,927 50 ,004
tidak ,177 13 ,200* ,938 13 ,430
*. This is a lower bound of the true significance.
Nonparametric Tests
Rejimen Pengobatan * Dislipidemia Crosstabulation
Dislipidemia
Total ya tidak
Rejimen Pengobatan Naive Count 20 1 21
Expected Count 16,7 4,3 21,0
% within Rejimen
Pengobatan 95,2% 4,8% 100,0%
% within Dislipidemia 40,0% 7,7% 33,3%
Zidovudine Count 12 9 21
Expected Count 16,7 4,3 21,0
% within Rejimen
Pengobatan 57,1% 42,9% 100,0%
% within Dislipidemia 24,0% 69,2% 33,3%
Tenofovir Count 18 3 21
Expected Count 16,7 4,3 21,0
% within Rejimen
Pengobatan 85,7% 14,3% 100,0%
Total Count 50 13 63
Expected Count 50,0 13,0 63,0
% within Rejimen
Pengobatan 79,4% 20,6% 100,0%
% within Dislipidemia 100,0% 100,0% 100,0%
Chi-Square Tests
Value df
Asymp. Sig.
(2-sided)
Pearson Chi-Square 10,080a 2 ,006
Likelihood Ratio 10,196 2 ,006
Linear-by-Linear Association ,572 1 ,449
N of Valid Cases 63
a. 3 cells (50,0%) have expected count less than 5. The minimum
expected count is 4,33.
Rejimen Pengobatan * Dislipidemia Crosstabulation
Dislipidemia
Total ya tidak
Rejimen Pengobatan Naive Count 20 1 21
Expected Count 16,0 5,0 21,0
% within Rejimen
Pengobatan 95,2% 4,8% 100,0%
% within Dislipidemia 62,5% 10,0% 50,0%
Zidovudine Count 12 9 21
Expected Count 16,0 5,0 21,0
% within Rejimen
Pengobatan 57,1% 42,9% 100,0%
% within Dislipidemia 37,5% 90,0% 50,0%
Total Count 32 10 42
Expected Count 32,0 10,0 42,0
% within Rejimen
Pengobatan 76,2% 23,8% 100,0%
Chi-Square Tests
Continuity Correctionb 6,431 1 ,011
Likelihood Ratio 9,383 1 ,002
Fisher's Exact Test ,009 ,004
Linear-by-Linear Association 8,200 1 ,004
N of Valid Cases 42
a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 5,00.
b. Computed only for a 2x2 table
Risk Estimate
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Rejimen
Pengobatan (Naive /
Zidovudine)
15,000 1,685 133,551
For cohort Dislipidemia = ya 1,667 1,137 2,443
For cohort Dislipidemia =
tidak ,111 ,015 ,801
N of Valid Cases 42
Rejimen Pengobatan * Dislipidemia Crosstabulation Dislipidemia
Total ya tidak
Rejimen Pengobatan Naive Count 20 1 21
% within Rejimen
Pengobatan 95,2% 4,8% 100,0%
% within Dislipidemia 52,6% 25,0% 50,0%
Tenofovir Count 18 3 21
% within Rejimen
Pengobatan 85,7% 14,3% 100,0%
% within Dislipidemia 47,4% 75,0% 50,0%
Total Count 38 4 42
% within Rejimen
Pengobatan 90,5% 9,5% 100,0%
Chi-Square Tests
Continuity Correctionb ,276 1 ,599
Likelihood Ratio 1,152 1 ,283
Fisher's Exact Test ,606 ,303
Linear-by-Linear Association 1,079 1 ,299
N of Valid Cases 42
a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 2,00.
b. Computed only for a 2x2 table
Risk Estimate
Value
95% Confidence Interval
Lower Upper
Odds Ratio for Rejimen
Pengobatan (Naive /
Tenofovir)
3,333 ,318 34,989
For cohort Dislipidemia = ya 1,111 ,911 1,356
For cohort Dislipidemia =
Block 0: Beginning Block
Classification Tablea,b
Observed
Predicted
Dislipidemia Percentage
Correct tidak ya
Step 0 Dislipidemia tidak 0 13 ,0
ya 0 50 100,0
Overall Percentage 79,4
a. Constant is included in the model.
b. The cut value is ,500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step 0 Constant 1,347 ,311 18,722 1 ,000 3,846
Variables not in the Equation
Score df Sig.
Omnibus Tests of Model Coefficients Chi-square df Sig.
Step 1 Step 16,049 4 ,003
Block 16,049 4 ,003
Model 16,049 4 ,003
Model Summary
Step -2 Log likelihood
Cox & Snell R
Square
Nagelkerke R
Square
1 48,095a ,225 ,352
a. Estimation terminated at iteration number 6 because
Classification Tablea
Observed
Predicted
Dislipidemia Percentage
Correct tidak ya
Step 1 Dislipidemia tidak 5 8 38,5
ya 5 45 90,0
Overall Percentage 79,4
a. The cut value is ,500
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
a. Variable(s) entered on step 1: usia, CD, rejimen.
Logistic Regression
Block 0: Beginning Block
Classification Tablea,b
Observed
Predicted
Dislipidemia Percentage
Correct tidak ya
Step 0 Dislipidemia tidak 0 13 ,0
ya 0 50 100,0
Overall Percentage 79,4
a. Constant is included in the model.
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
Step 0 Constant 1,347 ,311 18,722 1 ,000 3,846
Variables not in the Equation
Score df Sig.
Omnibus Tests of Model Coefficients Chi-square df Sig.
Step 1 Step 16,011 3 ,001
Block 16,011 3 ,001
Model 16,011 3 ,001
Model Summary
Step -2 Log likelihood
Cox & Snell R
Square
Nagelkerke R
Square
1 48,133a ,224 ,351
a. Estimation terminated at iteration number 6 because
parameter estimates changed by less than ,001.
Classification Tablea
Observed
Predicted
Dislipidemia Percentage
Correct tidak ya
Step 1 Dislipidemia tidak 5 8 38,5
ya 5 45 90,0
Overall Percentage 79,4
Variables in the Equation
B S.E. Wald df Sig. Exp(B)
95% C.I.for EXP(B)
Lower Upper
Step 1a usia ,112 ,056 4,053 1 ,044 1,118 1,003 1,247
rejimen 9,421 2 ,009
rejimen(1) -3,022 1,164 6,745 1 ,009 ,049 ,005 ,476
rejimen(2) -1,035 1,221 ,718 1 ,397 ,355 ,032 3,892
Constant -,634 1,978 ,103 1 ,749 ,531
NO Nama
KETERANGAN MASTER TABEL
Rejimen ARV
(2) Tidak bekerja (3) Ibu Rumah Tangga (4) Petani(5) PNS
(6) Karyawan swasta (7) Supir (5) Deli Serdang (6) Nias